XERS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Xeris Biopharma Holdings Inc. (XERS) is not a strong buy at this time for a beginner, long-term investor. While the company has shown strong revenue growth, its net income and EPS have significantly declined. The technical indicators and trading sentiment do not provide a clear bullish signal, and the stock is currently trading below key pivot levels. Additionally, there are no strong proprietary trading signals or recent influential trades to support an immediate buy decision.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 44.758, and moving averages are converging, suggesting no clear trend. The stock is trading below the pivot level of 6.709, with support at 6.388 and resistance at 7.03.
Barclays initiated coverage with an Overweight rating and a $9 price target, citing easing pricing headwinds and opportunities in the specialty pharmaceuticals sector. The company has filed a patent infringement lawsuit to protect its product Recorlev® until 2040, which could secure its market position.
The stock has declined by -3.34% in the regular market and -3.56% in pre-market trading. Net income and EPS have significantly dropped YoY, and there are no significant hedge fund or insider trading trends. The options data indicates low put-call ratios, suggesting limited bullish sentiment.
In Q3 2025, revenue increased by 37.06% YoY to $74.38M, but net income dropped by -103.95% YoY to $621K, and EPS fell to 0, down -100% YoY. Gross margin improved to 81.57%, up 16.60% YoY.
Barclays initiated coverage with an Overweight rating and a $9 price target, highlighting improving investor sentiment and easing pricing headwinds in the specialty pharmaceuticals sector.
